Overview Dividends

(PHAT) Phathom Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US71722W1071

Tablet, Antibiotic, Proton-Pump, Inhibitor

Pharmaceuticals
Market Cap in USD: 1,180m
IPO / Inception: 2019-10-25
Return 12m vs S&P 500: 83.0%

EPS (Earnings per Share)

EPS (Earnings per Share) of PHAT over the last years for every Quarter: "2020-12": -1.58, "2021-03": -0.96, "2021-06": -1, "2021-09": -0.98, "2021-12": -0.95, "2022-03": -1.07, "2022-06": -1.33, "2022-09": -1.32, "2022-12": -1.33, "2023-03": -0.89, "2023-06": -0.84, "2023-09": -0.76, "2023-12": -1.39, "2024-03": -1.42, "2024-06": -1.56, "2024-09": -1.32, "2024-12": -1.05, "2025-03": -1.07, "2025-06": -0.79, "2025-09": -0.15, "2025-12": 0,
EPS CAGR: 31.50%
EPS Trend: 55.7%
Last SUE: 1.42
Qual. Beats: 2

Revenue

Revenue of PHAT over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.682, 2024-03: 1.912, 2024-06: 7.324, 2024-09: 16.352, 2024-12: 29.664, 2025-03: 28.519, 2025-06: 39.503, 2025-09: 49.504, 2025-12: null,
Rev. CAGR: 597.03%
Rev. Trend: 91.3%
Last SUE: 1.27
Qual. Beats: 2

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 66.4%
Value at Risk 5%th 96.3%
Relative Tail Risk -11.79%
Reward TTM
Sharpe Ratio 1.08
Alpha 96.92
CAGR/Max DD 0.34
Character TTM
Hurst Exponent 0.562
Beta 1.431
Beta Downside 1.622
Drawdowns 3y
Max DD 88.26%
Mean DD 36.38%
Median DD 35.70%

Description: PHAT Phathom Pharmaceuticals December 01, 2025

Phathom Pharmaceuticals (NASDAQ: PHAT) is a U.S.-based biopharma that concentrates on gastrointestinal therapeutics, most notably its vonoprazan-based product VOQUEZNA. The company has reported successful Phase III outcomes for VOQUEZNA in erosive GERD, for the VOQUEZNA Triple Pak and Dual Pak in Helicobacter pylori eradication, and for VOQUEZNA (alone or with vonoprazan) in non-erosive GERD and eosinophilic esophagitis across adult and adolescent cohorts.

Key operational metrics that investors watch include the projected 2025 peak-sale potential of $350 million for the GERD franchise (based on a 10 % market share of the $3.5 billion U.S. GERD market) and a 30-day H. pylori eradication rate of 92 % in the Phase III Triple Pak trial, which exceeds the 85 % benchmark set by current standard-of-care regimens. The gastrointestinal drug segment is benefitting from an aging population (U.S. adults ≥ 65 years projected to reach 80 million by 2030) and a shift toward oral, fast-acting acid suppressors that promise higher adherence and lower healthcare utilization.

For a deeper dive into PHAT’s valuation assumptions and comparable peer analysis, consider exploring the data and tools available on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-274.6m TTM) > 0 and > 6% of Revenue (6% = 8.83m TTM)
FCFTA -0.94 (>2.0%) and ΔFCFTA -29.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 77.90% (prev 1174 %; Δ -1097 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.94 (>3.0%) and CFO -225.2m > Net Income -274.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 2.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (73.4m) change vs 12m ago 13.57% (target <= -2.0% for YES)
Gross Margin 87.25% (prev 82.83%; Δ 4.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 46.93% (prev 6.79%; Δ 40.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2.91 (EBITDA TTM -203.6m / Interest Expense TTM 70.3m) >= 6 (WARN >= 3)

Altman Z'' -23.41

(A) 0.48 = (Total Current Assets 207.8m - Total Current Liabilities 93.1m) / Total Assets 240.3m
(B) -6.09 = Retained Earnings (Balance) -1.46b / Total Assets 240.3m
warn (B) unusual magnitude: -6.09 — check mapping/units
(C) -0.65 = EBIT TTM -204.3m / Avg Total Assets 313.7m
(D) -2.21 = Book Value of Equity -1.46b / Total Liabilities 662.8m
Total Rating: -23.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 66.31

1. Piotroski 2.0pt
2. FCF Yield -21.50%
3. FCF Margin data missing
4. Debt/Equity -0.01
5. Debt/Ebitda 0.65
6. ROIC - WACC (= 95.70)%
7. RoE 77.32%
8. Rev. Trend 91.31%
9. EPS Trend 55.70%

What is the price of PHAT shares?

As of January 07, 2026, the stock is trading at USD 16.37 with a total of 377,198 shares traded.
Over the past week, the price has changed by -3.25%, over one month by +9.87%, over three months by +41.00% and over the past year by +115.11%.

Is PHAT a buy, sell or hold?

Phathom Pharmaceuticals has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy PHAT.
  • Strong Buy: 6
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the PHAT price?

Issuer Target Up/Down from current
Wallstreet Target Price 22.9 39.9%
Analysts Target Price 22.9 39.9%
ValueRay Target Price 17.4 6.4%

PHAT Fundamental Data Overview January 03, 2026

Market Cap USD = 1.18b (1.18b USD * 1.0 USD.USD)
P/S = 8.0181
P/B = 25.3678
Beta = 0.433
Revenue TTM = 147.2m USD
EBIT TTM = -204.3m USD
EBITDA TTM = -203.6m USD
Long Term Debt = 207.1m USD (from longTermDebt, last quarter)
Short Term Debt = 591.0k USD (from shortTermDebt, last quarter)
Debt = 2.71m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -132.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.05b USD (1.18b + Debt 2.71m - CCE 135.2m)
Interest Coverage Ratio = -2.91 (Ebit TTM -204.3m / Interest Expense TTM 70.3m)
FCF Yield = -21.50% (FCF TTM -225.3m / Enterprise Value 1.05b)
FCF Margin = -153.0% (FCF TTM -225.3m / Revenue TTM 147.2m)
Net Margin = -186.5% (Net Income TTM -274.6m / Revenue TTM 147.2m)
Gross Margin = 87.25% ((Revenue TTM 147.2m - Cost of Revenue TTM 18.8m) / Revenue TTM)
Gross Margin QoQ = 87.50% (prev 87.25%)
Tobins Q-Ratio = 4.36 (Enterprise Value 1.05b / Total Assets 240.3m)
Interest Expense / Debt = 593.5% (Interest Expense 16.1m / Debt 2.71m)
Taxrate = 21.0% (US default 21%)
NOPAT = -161.4m (EBIT -204.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.23 (Total Current Assets 207.8m / Total Current Liabilities 93.1m)
Debt / Equity = -0.01 (negative equity) (Debt 2.71m / totalStockholderEquity, last quarter -422.5m)
Debt / EBITDA = 0.65 (negative EBITDA) (Net Debt -132.4m / EBITDA -203.6m)
Debt / FCF = 0.59 (negative FCF - burning cash) (Net Debt -132.4m / FCF TTM -225.3m)
Total Stockholder Equity = -355.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -114.3% (out of range, set to none)
RoE = 77.32% (negative equity) (Net Income TTM -274.6m / Total Stockholder Equity -355.1m)
RoCE = 138.0% (negative capital employed) (EBIT -204.3m / Capital Employed (Equity -355.1m + L.T.Debt 207.1m))
RoIC = 107.0% (negative operating profit) (NOPAT -161.4m / Invested Capital -150.9m)
WACC = 11.26% (E(1.18b)/V(1.18b) * Re(11.29%) + (debt cost/tax rate unavailable))
Discount Rate = 11.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.63%
Fair Price DCF = unknown (Cash Flow -225.3m)
EPS Correlation: 55.70 | EPS CAGR: 31.50% | SUE: 1.42 | # QB: 2
Revenue Correlation: 91.31 | Revenue CAGR: 597.0% | SUE: 1.27 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.30 | Chg30d=+0.143 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.10 | Chg30d=+0.063 | Revisions Net=-1 | Growth EPS=+95.7% | Growth Revenue=+82.9%

Additional Sources for PHAT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle